Love Health

A large number of pre-clinical data on the abdominal cavity, as well as anatomy, physiology and ovarian cancer biology to understand all the tips given to local cytotoxic abdominal treatment of ovarian cancer is very reasonable. â…  period of intra-abdominal chemotherapy clinical trial confirmed the abdominal chemotherapy drugs and chemotherapy itself, techniques of security, confirmed the abdominal chemotherapy in the pharmacokinetic advantage.

â…¡ in a number of multi-center clinical trials, the results of the operation confirmed that about 20% to 40% in the second category of cisplatin-based intraperitoneal chemotherapy in patients with complete remission, some of the residual cancer in patients with <0.5 cm î–„ prior to the acceptance of Platinum-based chemotherapy effective system of the body.

Intraperitoneal chemotherapy in the study, there are 3 â…¢ well-designed clinical trials results of the most significant.

1. Cisplatin and intraperitoneal administration of intravenous route of administration of comparison:

Research into ≤ 2 cm of residual cancer patients, found that peritoneal administration can reduce the tinnitus and neutropenia occurred in the rate of increase in abdominal pain incidence, to extend the survival time of patients (intraperitoneal administration of intravenous drug delivery 49 months to 41 months, P = 0.02).

2. Paclitaxel and cisplatin + intravenous administration of intraperitoneal cisplatin and paclitaxel + compared with intravenous administration:

Research into the largest 1 cm of residual cancer patients, administration cisplatin celiac patients receive treatment 2 of carboplatin chemotherapy for cancer of the residual tumor cut out of the chemical. The results showed that intraperitoneal administration of cisplatin group of progression-free survival was significantly longer period (28 months to 22 months), overall survival was also significantly longer (63 months to 52 months).

3. Paclitaxel and cisplatin + intravenous administration of intraperitoneal cisplatin and paclitaxel + (+ intravenous administration of intra-abdominal) comparison:

Group Test 1st day of intravenous drug Taxol, 2 platinum Tianshun abdominal delivery, the 8th day intraperitoneal administration of Taxol, each of the 21-day course of treatment. The results confirmed that abdominal chemotherapy could improve the survival rate of progress.

These results confirm â…¢ period, compared with systemic chemotherapy, intra-abdominal injection of cisplatin, as first-line chemotherapy allows small residual foci of patients with advanced ovarian cancer recurrence and mortality of 20% to 25%. Unfortunately, researchers have overlooked the importance of these findings, perhaps because of cisplatin cause side effects such as vomiting, so doctors do not want to implement, the patient is not willing to accept.

How to reduce the toxicity of the abdominal chemotherapy has two suggestions:

1. To reduce the amount of cisplatin from 100 mg/m2 to 75 mg/m2;

2. Substituted with carboplatin and cisplatin in ovarian cancer of the abdominal chemotherapy with cisplatin and carboplatin to replace it is very reasonable, and the above-mentioned period â…  â…¡ clinical trials have confirmed the abdominal chemotherapy carboplatin safety and efficacy.

At present, is still a need for the test is that the small residual cancer in patients with ovarian cancer, intraperitoneal administration of carboplatin with carboplatin administered separately vein as the first-line chemotherapy for direct comparison. In the next few months, the United States Association of Gynecologic Oncology (GOG) will launch a similar study, if the study could be “intra-abdominal chemotherapy is superior to intravenous chemotherapy,” As a result, small residual cancer in patients with advanced ovarian cancer treatment modalities will be Change.